Toggle Main Menu Toggle Search

Open Access padlockePrints

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

Lookup NU author(s): Harriet Southgate, Dr Lindi Chen, Professor Nicola CurtinORCiD, Professor Deborah Tweddle

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© Copyright © 2020 Southgate, Chen, Curtin and Tweddle.Despite intensive multimodal therapy, the survival rate for high risk neuroblastoma (HR-NB) remains <50%. Most cases initially respond to treatment but almost half will subsequently relapse with aggressive treatment resistant disease. Novel treatments exploiting the molecular pathology of NB and/or overcoming resistance to current genotoxic therapies are needed before survival rates can significantly improve. DNA damage response (DDR) defects are frequently observed in HR-NB including allelic deletion and loss of function mutations in key DDR genes, oncogene induced replication stress and cell cycle checkpoint dysfunction. Exploiting defects in the DDR has been a successful treatment strategy in some adult cancers. Here we review the genetic features of HR-NB which lead to DDR defects and the emerging molecular targeting agents to exploit them.


Publication metadata

Author(s): Southgate HED, Chen L, Curtin NJ, Tweddle DA

Publication type: Review

Publication status: Published

Journal: Frontiers in Oncology

Year: 2020

Volume: 10

Online publication date: 03/04/2020

Acceptance date: 03/03/2020

ISSN (electronic): 2234-943X

Publisher: Frontiers Media S.A.

URL: https://doi.org/10.3389/fonc.2020.00371

DOI: 10.3389/fonc.2020.00371


Share